皮科林酸盐减轻结肠炎症和增强壁功能在性结肠炎的老鼠模型
Gonca Han1, Kaan Furkan Hamarat2, Rana Taşdemir3
1School of Medicine, Department of Physiology, Sakarya University, Korucuk Mah. Konuralp Bulvarı No:81/1 Korucuk Kampüsü, 54100, Adapazarı, Türkiye.
Biological trace element research
|September 27, 2025
概括
皮科林酸补充剂显示对大肠炎的保护作用在实验性大鼠中. 它可以减少炎症和氧化应激,同时改善肠道屏障功能.
科学领域:
- 胃肠病学和营养科学 胃肠病学和营养科学
- 分子和细胞生物学分子和细胞生物学
背景情况:
- 性结肠炎 (UC) 症状可能会因缺而恶化.
- 对于UC的皮科林酸的治疗潜力尚不清楚.
研究的目的:
- 为了研究皮科林酸盐在酸 (AA) 诱导的大肠炎的小鼠模型中的保护作用.
- 评估皮科林酸盐对氧化应激,炎症和肠道屏障完整性的影响.
主要方法:
- 雄性Sprague Dawley大鼠被分为对照组和结肠炎组.
- 大肠炎是使用酸 (AA) 诱导的.
- 在AA诱导之前,老鼠接受了用盐水,,皮科林酸盐或硫法萨拉进行预处理. 结肠组织分析了各种标记物.
主要成果:
- AA诱导的大肠炎显著增加炎症标志物 (MDA,MPO,TNF-α,IL-6) 和组织损伤.
- 大肠炎还降低了抗氧化剂水平 (GSH) 和紧结蛋白 (occludin,claudin-1).
- 和皮科林酸预处理减轻了这些负面影响,减少了损伤和炎症,同时增强了抗氧化剂和紧结蛋白.
结论:
- 皮科林酸显示出对实验性结肠炎的保护作用.
- 这些好处归因于氧化和炎症损伤的减少.
- 在大肠炎模型中,皮科林酸盐支持肠道屏障的完整性.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
413
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
413
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
604
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
604
Drugs for Treatment of Constipation-Predominant IBS
664
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
664
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K
Inflammatory Bowel Disease IV: Pharmacological Management
427
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
427
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K


